Sanofi-Aventis To File For Menactra Use In Infants
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm sees pharmacoeconomic advantage for two-dose regimen at nine and 12 months.
You may also be interested in...
Sanofi Pasteur Nets Flu Vaccine Via Acambis Purchase
Early C. difficile program comes along with $550 million deal.
Sanofi Pasteur’s Five-In-One Vaccine Approved
Next step for Pentacel is the June 25 ACIP Vaccines for Children vote.
Novartis Meningitis Blockbuster Strategy Key To Firm’s Vaccine Growth
Novartis plans to submit ACWY meningitis BLA in the second half, putting Menveo on track for approval in 2009.